Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00626444 |
|
Recruitment Status :
Terminated
(Slow accrual)
First Posted : February 29, 2008
Results First Posted : December 10, 2014
Last Update Posted : November 29, 2016
|
Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Information provided by (Responsible Party):
Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Study Type | Interventional |
|---|---|
| Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
| Condition |
Non-Hodgkin Lymphoma |
| Intervention |
Drug: Intravenous vitamin C |
| Enrollment | 2 |
Participant Flow
| Recruitment Details | |
| Pre-assignment Details |
| Arm/Group Title | Vitamin C |
|---|---|
 Arm/Group Description |
Intravenous vitamin C Intravenous vitamin C: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks. |
| Period Title: Overall Study | |
| Started | 2 |
| Completed | 2 |
| Not Completed | 0 |
Baseline Characteristics
| Arm/Group Title | Vitamin C | |
|---|---|---|
|
Arm/Group Description |
Intravenous vitamin C Intravenous vitamin C: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks. |
|
| Overall Number of Baseline Participants | 2 | |
|
Baseline Analysis Population Description |
[Not Specified]
|
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||
| Number Analyzed | 2 participants | |
| 55.3 (2.9) | ||
|
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||
| Number Analyzed | 2 participants | |
| <=18 years |
0 0.0%
|
|
| Between 18 and 65 years |
2 100.0%
|
|
| >=65 years |
0 0.0%
|
|
|
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
| Number Analyzed | 2 participants | |
| Female |
1 50.0%
|
|
| Male |
1 50.0%
|
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
| Number Analyzed | 2 participants | |
| American Indian or Alaska Native |
0 0.0%
|
|
| Asian |
0 0.0%
|
|
| Native Hawaiian or Other Pacific Islander |
0 0.0%
|
|
| Black or African American |
0 0.0%
|
|
| White |
1 50.0%
|
|
| More than one race |
0 0.0%
|
|
| Unknown or Not Reported |
1 50.0%
|
|
|
Ethnicity (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
| Number Analyzed | 2 participants | |
| Hispanic or Latino |
1 50.0%
|
|
| Not Hispanic or Latino |
1 50.0%
|
|
| Unknown or Not Reported |
0 0.0%
|
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
| United States | Number Analyzed | 2 participants |
| 2 | ||
Outcome Measures
Adverse Events
Limitations and Caveats
Study was terminated due to poor accrual. No reportable data has been collected for any of the specified outcome measures.
More Information
Results Point of Contact
| Name/Title: | Daniel Monti, MD |
| Organization: | Thomas Jefferson University |
| Phone: | 215-955-4410 |
| EMail: | Daniel.Monti@jefferson.edu |
| Responsible Party: | Thomas Jefferson University ( Sidney Kimmel Cancer Center at Thomas Jefferson University ) |
| ClinicalTrials.gov Identifier: | NCT00626444 |
| Other Study ID Numbers: |
07U.21 |
| First Submitted: | February 21, 2008 |
| First Posted: | February 29, 2008 |
| Results First Submitted: | November 24, 2014 |
| Results First Posted: | December 10, 2014 |
| Last Update Posted: | November 29, 2016 |